Advances in medical sciences · 2009
Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mazerska M, Myśliwiec M
Аннотация
PURPOSE: Angiotensin-converting-enzyme inhibitors (ACEIs) provide renal protection in patients with type 2 diabetes and microalbuminuria.
MATERIAL AND METHODS: In the presented study we followed 34 stable, type 2 diabetic patients with persistent albuminuria treated with maximal doses of ACEIs as a part of their anti-hypertensive treatment. Telmisartan--an angiotensin receptor blocker (ARB)--in a dose of 40 mg was added to the treatment and the patients were observed for 12 weeks. We measured creatinine clearance, 24-hour urinary albumin excretion, before and after 12 weeks of combined therapy.
RESULTS: The addition of telmisartan resulted in a significant reduction of albuminuria from median 157 to 67 mg/24h. No change in creatinine clearance was observed (93 vs 97 ml/min).
CONCLUSION: The addition of telmisartan to a maximum dose of ACEI is safe and results in further albuminuria decrease in patients with type 2 diabetes and incipient nephropathy.
MATERIAL AND METHODS: In the presented study we followed 34 stable, type 2 diabetic patients with persistent albuminuria treated with maximal doses of ACEIs as a part of their anti-hypertensive treatment. Telmisartan--an angiotensin receptor blocker (ARB)--in a dose of 40 mg was added to the treatment and the patients were observed for 12 weeks. We measured creatinine clearance, 24-hour urinary albumin excretion, before and after 12 weeks of combined therapy.
RESULTS: The addition of telmisartan resulted in a significant reduction of albuminuria from median 157 to 67 mg/24h. No change in creatinine clearance was observed (93 vs 97 ml/min).
CONCLUSION: The addition of telmisartan to a maximum dose of ACEI is safe and results in further albuminuria decrease in patients with type 2 diabetes and incipient nephropathy.
Предметные рубрики MeSH
AgedAlbuminuriaAnalysis of VarianceAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBenzimidazolesBenzoatesCreatinineDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionDrug Therapy, CombinationFemaleHumansHypertensionMaleMiddle AgedPilot ProjectsTelmisartan